Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
Phase 3
Completed
NCT05827978
| Condition | Seasonal Influenza |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | ModernaTX, Inc. |
|---|
| Status | Completed |
|---|
| Enrollment | 8,411 participants |
|---|
| Interventions | mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine |
|---|
| Start date | Apr 17, 2023 |
|---|
| Completion date | Jun 24, 2024 |
|---|
| Results posted | Jul 10, 2025 |
|---|
Summary
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody Levels as Measured by Hemagglutination Inhibition (HAI)
Day 29 · titer
| Part A: Fluarix QIV | 147.49 titer |
|---|
| Part A: mRNA-1010 | 220.17 titer |
|---|
| Part B: Fluarix QIV | 137.90 titer |
|---|
| Part B: mRNA-1010 | 208.10 titer |
|---|
| Part C: Fluzone HD QIV | 130.09 titer |
|---|
| Part C: mRNA-1010 | 174.81 titer |
|---|
Percentage of Participants Reaching Seroconversion, as Measured by HAI
Day 29 · percentage of participants
| Part A: Fluarix QIV | 34.9 percentage of participants |
|---|
| Part A: mRNA-1010 | 50.2 percentage of participants |
|---|
| Part B: Fluarix QIV | 45.0 percentage of participants |
|---|
| Part B: mRNA-1010 | 64.4 percentage of participants |
|---|
| Part C: Fluzone HD QIV | 36.3 percentage of participants |
|---|
| Part C: mRNA-1010 | 49.7 percentage of participants |
|---|
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Up to 7 days after study injection · Participants
| Part A: Fluarix QIV | 682 Participants |
|---|
| Part A: mRNA-1010 | 1060 Participants |
|---|
| Part B: Fluarix QIV | 796 Participants |
|---|
| Part B: mRNA-1010 | 1158 Participants |
|---|
| Part C: Fluzone HD QIV | 734 Participants |
|---|
| Part C: mRNA-1010 | 1131 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.